# Quality of life in head and neck cancer survivors: the Big Data for

- **Quality of Life study** 2
- Mauricio Moreira-Soares<sup>1\*</sup>, Erlend I. F. Fossen<sup>1</sup>, Katherine J. Taylor<sup>2</sup>, Susanne Singer<sup>2</sup>, Katrina Hurley<sup>3a</sup>, Steve Thomas<sup>3b</sup>, Miranda Pring<sup>3b</sup>, Andrew Ness<sup>3b</sup>, Stefano Cavalieri<sup>4,5</sup>, Claudia Vener<sup>6</sup>, Laura Lopez-Perez<sup>7</sup>, Maria Fernanda Cabrera-Umpierrez<sup>7</sup>, Giuseppe Fico<sup>7</sup>, Arnoldo Frigessi<sup>1,8</sup>, Lisa Licitra<sup>4,5</sup>, Marissa LeBlanc<sup>1,9</sup>, on behalf of the BD4QoL consortium 3
- 4
- 5
- <sup>1</sup> Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway 7
- <sup>2</sup> Institute of Medical Biostatistics, Epidemiology, and Informatics, University Medical Centre 8
- 9 Mainz, Germany

1

- <sup>3</sup> Bristol Head & Neck 5000 Study, 3a University Hospitals Bristol and Weston NHS Foundation 10
- Trust, Bristol, UK, 3b Bristol Dental School, University of Bristol, United Kingdom 11
- <sup>4</sup> Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 12
- 13 Milan, Italy
- <sup>5</sup> Department of Oncology and Hemato-oncology, University of Milan, Italy 14
- <sup>6</sup> Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 15
- Milan, Italy 16
- <sup>7</sup> Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, Madrid, 17
- 18 **Spain**
- <sup>8</sup> Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway 19
- <sup>9</sup> Norwegian Institute of Public Health, Oslo, Norway 20
- \* Correspondence: 21
- 22 Corresponding Author
- m.m.soares@medisin.uio.no 23
- Keywords: quality of life, patient-reported outcomes, survivors, European cohort, reference 26
- 27 values

24

25

29 Abstract

- 30 **Background:** The Big Data for Quality of Life (BD4QoL) study investigates quality of life (QoL) in
- 31 head and neck cancer (HNC) survivors, focusing on survivorship and characterizing survivor
- 32 demographics.

46

- 33 **Methods:** We screened data from 5 studies across Europe (N=7276) and included patients with a
- diagnosis of squamous cell carcinoma (oral cavity, hypopharynx, larynx, oropharynx, nasal cavity
- and paranasal sinuses), treated with curative intent, alive after treatment, TNM 7<sup>th</sup> ed. stages I, II, III,
- 36 IVa and IVb, with availability of QoL questionnaires.
- 37 **Results:** The cohort of 4448 HNC survivors primarily includes men (78%) with median age 61 years.
- 38 Most received radiotherapy (75%) and had a history of smoking (78%). Survivors' scores on EORTC
- 39 QLQ-C30 functioning scales indicated high functioning, with prevalent symptoms of fatigue, pain,
- and insomnia. Lower rates of missing data were observed in older patients, those with higher
- 41 education and income levels, nonsmokers, married individuals, and patients not treated with
- radiotherapy. The odds ratios ranged from 0.47 to 0.99, indicating these factors may predict more
- 43 consistent QoL data reporting in HNC survivors.
- 44 **Conclusions:** These data support the development and validation of clinical prediction models for
- 45 QoL in HNC survivors in a multicentre randomized controlled trial.

#### 1 Introduction

48

The incidence of head and neck cancer (HNC) has been increasing worldwide in the last years and 49 reached 1.1 million new diagnoses in 2016<sup>1,2</sup>. Globally, it is the seventh most common type of 50 cancer<sup>3,4</sup>. At the same time, the overall 5-year survival has improved considerably in the last decades, 51 changing from 55% in 1992-1996 to 66% in 2002-2006<sup>5</sup>, which makes long-term quality of life 52 53 (QoL) a key concern for patients. These changes in survival can be partially explained by better 54 treatments and a deeper understanding of the disease mechanisms, but also due to an increasing proportion of human papilloma virus (HPV)-induced oropharyngeal tumours which mainly affect a 55 younger population with fewer comorbidities and better prognosis<sup>6-10</sup>. According to the stage of the 56 57 disease and patient status (i.e., performance status, comorbidities). HNC can be treated with either single modality or multimodal approaches, including combinations of surgery, radiotherapy, and 58 systemic therapy<sup>11</sup>. Despite the intention to cure, recurrences in the local and regional areas, as well 59 as distant relapses, are common <sup>12,13</sup>. Additionally, these treatment methods often lead to significant toxicities and long-term complications <sup>14–16</sup>. Consequently, the QoL of HNC survivors is frequently 60 61 compromised. Health related QoL has been found to be associated with clinical endpoints in 62 oncology patients<sup>17</sup>, particularly studies have shown strong evidence of association between physical 63 functioning and global QoL change with overall survival in individuals with HNC<sup>18</sup>. However, there 64 is limited research on the long-term changes in QoL and the factors that influence these changes. 65 66 Existing evidence suggests that global QoL tends to recover within 12 months after HNC treatment, 67 but late complications persist, including declines in physical functioning, fatigue, xerostomia (dry mouth), and sticky saliva<sup>19</sup>, affecting overall QoL. Furthermore, the available literature on QoL in 68 69 HNC survivors is relatively limited, particularly concerning long-term changes and determinants of QoL over time<sup>20</sup>. Most studies have focused on short-term recovery, but there is a lack of information 70 regarding the sustained effects and late sequelae experienced by HNC survivors<sup>21,22</sup>. Investigating 71 72 these factors is essential for optimizing patient care, identifying potential interventions to alleviate 73 specific needs, and improving survivorship outcomes.

- 74 This study describes the creation of the multi-national Big Data for Quality of Life (BD4QoL)
- historical cohort, which was established to investigate QoL in HNC survivors. This cohort will be
- 76 used for research to better understand the OoL trajectory in HNC survivors.
- 77 The aim of the study is to define and describe clinical, demographic, quality of life and behavioural
- 78 characteristics of the patients in the BD4QoL historical cohort.

## **79 2 Methods**

80

#### 2.1 Quality of life questionnaires

- 81 The EORTC QLQ-C30 is a questionnaire developed by the European Organization for Research and
- 82 Treatment of Cancer, for assessing the quality of life of cancer patients  $\frac{23,24}{2}$ . This questionnaire is a
- Patient Reported Outcome (PRO) instrument which contains 30 questions that compose 10 sub-scales
- 84 divided in three groups: functional sub-scales (physical function, role function, cognitive function,
- 85 emotional function and social function), symptom sub-scales (pain, fatigue, nausea/vomiting) and
- chotional function and social functions, symptom sub-scales (pain, fatigue, nausea vointing) and
- 86 global health status (GHS)/quality of life. In addition, it contains 6 individual items to assess:
- 87 dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties. All scales and
- single-item measures range in score from 0 to 100. A high scale score represents a higher response
- 89 level. Thus, a high score for a functional scale represents a high/healthy level of functioning, a high
- 90 score for GHS/QoL represents a good overall QoL, but a high score for a symptom scale/item
- 91 represents a high level of symptoms/problems.

- The head and neck cancer module (EORTC QLQ-H&N35) incorporates seven multi-item scales that
- 93 assess pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality.
- 94 There are also eleven single items. For all items and scales, high scores indicate a higher degree of
- problems, i.e., there are no functioning scales.
- The EORTC QLQ-HN43 module is a revised and updated version of the head and neck cancer
- 97 module EORTC QLQ-HN35. The 43 items can be combined into the following scales: fear of
- progression, body image, dry mouth and sticky saliva, pain in the mouth, sexuality, problems with
- senses, problems with shoulder, skin problems, social eating, speech, swallowing, and problems with
- teeth. Single item scales are coughing, swelling in the neck, neurological problems, trismus, social
- 101 contact, weight loss, and problems with wound healing.

## 2.2 Cohort participants

## 103 **2.2.1 Datasets**

- We screened data collected in prior research projects at Istituto Nazionale dei Tumori (Italy),
- 105 University Hospitals Bristol and Weston NHS Foundation Trust, and University of Bristol (UK) and
- 106 University Medical Centre Mainz (UMM) in Germany to construct this cohort (Table 1). Data
- 107 collection was performed with the understanding and written consent of patients enrolled in the
- original studies.
- Head and Neck 5000 (HN5000) is a large UK based study of people with head and neck cancer<sup>25,26</sup>.
- The study is sponsored by University Hospitals Bristol and Weston NHS Foundation Trust (UHBW)
- and is run by UHBW and the University of Bristol. Briefly, 5511 people were recruited from 76 UK
- centres between 2011 and 2014 making it one of the largest prospective cohort studies of people with
- head and neck cancer in the world. The study collected more than 200 variables at several timepoints
- 114 (from diagnosis to 3 years follow-up), including clinical and demographic characteristics, standard
- OoL questionnaires, and information about physical and mental health. The inclusion criteria were 25:
- individuals over the age of 16 with a new head and neck primary cancer seen or discussed at an
- appropriate multidisciplinary team (MDT) meeting or clinic; People presenting with a cancer of
- unknown primary (CUP); those without a definitive histological diagnosis were eligible if the MDT
- decision was that the primary site was likely to be a HNC. The exclusion criteria included: people
- considered to meet the criteria for mental incapacity or vulnerability set out in the mental capacity/
- vulnerable adult act, recurrent HNC, a second head and neck cancer, skin cancer, lymphoma and a
- histological diagnosis of Carcinoma in Situ with no clear evidence of invasion (these patients were
- instological diagnosis of Caremonia in Situ with no clear evidence of invasion (these patients were
- eligible if later upstaged following MDT discussion); Patients who had already commenced their
- cancer treatment (with the exception of those whose treatment was also their diagnostic procedure)
- were also excluded.
- The second data set (UMM1)<sup>27</sup> was a prospective cohort study in patients before and after total
- laryngectomy (TLE). Further eligibility criteria were written informed consent and age of 18 years or
- older. The patients were interviewed in a face-to-face setting before the surgery (t1), shortly before
- discharge from the hospital (t2), at the end of rehabilitation (t3), one year after baseline (t4) as well as
- 130 two (t5) and three years (t6) after baseline. Participants also completed self-administered
- 131 questionnaires, including the EORTC QLQ-C30 and the EORTC QLQ-H&N35. A total of 389
- patients were enrolled between the years 2001-2011 from 13 hospitals in Germany.
- 133 The third data set (UMM2)<sup>28</sup> comes from a similar study, but this time in patients who were
- scheduled for partial laryngectomy (PLE). The study design and data collection were in parallel with

- the UMM1 study up to t4. Data collection began in 2007 and ended in 2015. A sample of 391
- patients were enrolled from 16 hospitals in Germany.
- The fourth data set (UMM3)<sup>29</sup> comes from an international validation study for the update of the
- EORTC QLQ-H&N35 questionnaire, the HN43 Phase IV study. In total, 812 patients from 18
- countries in Europe, the Americas and Asia were enrolled. Patients with cancer of the larynx (ICD-10
- 140 code C32), lip (C00), oral cavity (C01-06), salivary glands (C07-08), oro-hypopharynx (C09-10,
- 141 C12-14), nasopharynx (C11), nasal cavity (C30), nasal sinuses (C31), sarcoma in the head and neck
- region (C49), and lymph node metastases from Missing primary in the head and neck area (C77,
- 143 C80.0).were included. There were no restrictions regarding stage, recurrence status, or treatments
- planned or performed. Patients with a tumour of the eyes, orbit, thyroid, skin (even if in the head and
- neck area), or lymphomas in the head and neck region were excluded. Patients completed the
- questionnaires up to 14 days before start of treatment (t1), three months (t2), and six months
- thereafter (t3).

168

169

- 148 The Big Data to Decide (BD2Decide) project was a European multicentre observation study
- including 1537 HNC patients from Italy, Germany and the Netherlands<sup>30</sup>. The aim of this project was
- 150 to develop a multisource database to allow for prognostic prediction modelling in loco-regionally
- advanced HNC patients. The database was made of two cohorts: retrospective (diagnosis 2008-2014),
- and prospective (diagnosis 2015-2017). Main inclusion criteria were diagnosis of head and neck
- squamous cell carcinoma (HNSCC); stage III and IVA/B (based on AJCC/UICC seventh edition);
- receiving treatments with curative intent; availability of pre-treatment tumour specimen for biological
- analysis; availability of pre-treatment imaging scans for radiomic analysis; for patients enrolled
- prospectively, PROs were collected (EORTC C30, EORTC HN35 and EQ-5D-5L). The BD4QoL
- study included the prospective BD2Decide patients enrolled at one of the Italian cancer centres.
- 158 These longitudinal studies enrolled patients at diagnosis and before treatment initiation.
- 159 In the BD4QoL study, survivors are defined by the following inclusion and exclusion criteria:

#### **Inclusion criteria**

- 16. Non-metastatic head and neck cancers from one of the following subsites (ICD in annex 1):
- oral cavity, hypopharynx, larynx, oropharynx, nasopharynx, major or minor salivary glands,
- nasal cavity, paranasal sinuses.
- 164 2. Having received and concluded treatments with curative intent at time of study inclusion.
- 3. Being alive and disease-free at last post-treatment follow-up.
- 4. Stage I, II, III, IVa or IVb according to TNM 7<sup>th</sup> edition<sup>31</sup>.
- 167 5. Age  $\geq$ 18 years.

#### **Exclusion criteria**

- 1. Histologies other than squamous cell carcinoma and salivary gland carcinomas (e.g., sarcoma,
- melanoma are excluded). Thyroid cancers, neuroendocrine tumours and non-epithelial HNC
- (e.g., melanoma, sarcoma, etc.) are excluded.
- 2. Distant metastases at the time of study entry.

- 3. Any previous HNC unrelated to the primary HNC for which the participant was treated; premalignant lesions (e.g., leukoplakia, erythroplakia, lichen etc.) are allowed.
- 4. Subjects with previous malignancies (except localized non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, esophageal endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required during the study period.

## 2.2.2 Baseline definition

179

180

190

- 181 HNC survivors were defined as those patients alive and disease free after the end of treatment.
- However, end of treatment was not recorded in HN5000 and BD2Decide studies, and the QoL
- measurements were not exactly aligned with end of treatment (Table 2). Therefore, we defined the
- 184 BD4QoL "baseline" as the first available QoL measurement after the known or inferred end of
- treatment. The baseline for UMM1 and UMM2 studies is defined as 4 months after diagnosis and for
- 186 UMM3 is at 3 months, when end of treatment is recorded. For BD2Decide, the baseline is defined at
- 6 months after diagnosis, when all patients are assumed to have finished treatment in this study. In
- the case of HN5000, the baseline is established at 12 months after diagnosis, when all patients have
- 189 finished their curative treatment.

## 2.3 Data harmonization

- We performed data harmonization in a subset of variables to achieve compatible and comparable
- measurements across the different studies following the BD4QoL ontology<sup>32</sup>. In total, we harmonized
- 193 29 variables, consisting of 14 demographic and clinical variables and 15 QoL domains (

- Table 3). In addition, survival time and status were recorded in HN5000, BD2Decide and UMM1
- studies, while UMM2 and UMM3 presented interval censored data.
- Beyond the harmonised data, the studies that contributed data to this project recorded between
- hundreds to more than 2000 variables, which are therefore available in subsets of the BD4OoL
- 198 cohort. Two versions of the head and neck module of the EORTC questionnaire were used in the
- studies, in addition to demographics and several other questionnaires which attempt to capture fear of
- 200 recurrence, personal costs, hospital anxiety and depression, and general health.

## 2.4 Statistical analysis

201

- 202 Survival curves, stratified by study, were estimated using the Kaplan-Meier estimator. Survival
- 203 curves were only made for the BD2Decide, HN5000 and UMM1 studies, as other studies presented
- interval censored data with few measurements.
- To show the trajectory of overall quality of life over time, conditional on survival, we estimated the
- 206 mean GHS/QoL for each time point with a QoL measurement in each study. A 95% confidence
- interval for the means were obtain by bootstrap with 1000 bootstrap resamples per time point.
- 208 To explore the factors associated with missing quality of life (QoL) measurements, univariate logistic
- 209 regression analyses were performed. The response variable was a binary indicator for whether the
- 210 GHS/QoL scale was missing or not. This scale was chosen because it summarises global QoL. The
- 211 covariates considered in the respective univariate models were age, sex, tumour stage, tumour
- location, treatment, income, education, smoking status, and alcohol consumption.
- For interpretation of the EORTC QLQ-C30 scales we used the thresholds for clinical importance
- 214 (TCIs) proposed by Giesinger et al., which allow to identify patients with clinically important
- 215 problems or symptoms<sup>33</sup>.

#### 216 **3 Results**

217

## 3.1 Cohort characteristics

- 218 In total, 4448 HNC survivors were eligible for inclusion in this study (Figure 1). INT contributed 112
- subjects with QoL measurements under BD2Decide semantics 30,34,35. UMM contributed 883 subjects
- across 3 different longitudinal cohort studies (UMM1, UMM2, and UMM3), and Bristol contributed
- 221 3587 subjects using Head and Neck 5000 semantics and documentation available online
- 221 3387 subjects using Head and Neck 3000 semantics and documentation available offine
- 222 (headandneck5000.org.uk). All datasets contain quality of life scores based on the EORTC QLQ-C30
- and EORTC QLQ-H&N35 or EORTC QLQ-HN43 questionnaires.
- The patients in the cohort were predominately male (78%), had a median age of 61 years, had
- primarily low (47%) to medium education level (35%), most were married or lived with a partner
- 226 (68%), had a history of smoking (78%) and high alcohol consumption (median 84 alcohol
- 227 units<sup>1</sup>/month) (

\_

<sup>&</sup>lt;sup>1</sup> Alcohol unit is a dimensionless measurement unit defined as 10ml or 8g of pure alcohol.

228 Table 3). The education level variable presented distinct definitions across studies due to different 229 educational systems. Thus, the education levels were mapped to years of education and converted 230 into three categories: low (<10 years), medium (from 10 to 12 years), and high (>12 years). Overall, 231 75% of patients underwent radiotherapy, while 41% were treated with surgery and 38.6% received 232 chemotherapy. Nearly half of the patients (48%) were treated with at least two therapeutic modalities, 233 with the combination of chemotherapy and radiation being the most prevalent at 29%. The pairing of 234 radiotherapy and surgery was the next most common, involving 10% of patients, and a combination 235 of all three treatment approaches was used in 8% of cases. There was considerable heterogeneity 236 between the datasets in some characteristics, particularly tumour stage and tumour region, where 237 some studies had enrolled patients with only specific regions or tumour stages. For instance, in the 238 BD2Decide dataset, only loco-regionally advanced stage tumours were represented (stages III and 239 non-metastatic IV in TNM 7<sup>th</sup>). The UMM1 dataset predominantly consisted of advanced stage cases 240 as well with 79.2% of stage III and IV subjects, while the remaining datasets demonstrated a more 241 balanced distribution across tumour stages. In terms of tumour region, the UMM3 and HN5000 242 datasets had a limited number of cases involving the nasopharynx, salivary glands, nasal cavity, and 243 paranasal sinuses. In addition, the UMM1 and UMM2 datasets contained cases with tumours 244 overlapping multiple areas. In the integrated data, the three biggest tumour site groups were 245 oropharynx (37.1%), larynx (31.3%) and oral cavity (23.6%). Tumour stages I, II, III and IV were 246 distributed as 24.4%, 17.9%, 13.8% and 42.0% respectively.

- Survivors had an average probability of overall survival for one year after end of treatment of 0.94 [95% CI: 0.93, 0.95] and of 0.88 [0.87, 0.89] after 2 years. For BD2Decide, the 1- and 2-years overall survival were 0.95 [0.91, 0.99] and 0.86 [0.79, 0.94] respectively, for UMM1 0.88 [0.83, 0.93] and 0.76 [0.70, 0.83], and for HN5000 0.94 [0.93, 0.95] and 0.89 [0.88, 0.90] (see Figure 2).
- 251 Concerning the GHS/QoL of survivors, we observed that survivors presented some level of QoL 252 impairment at diagnosis and their OoL tends to decrease further during or immediately after 253 treatment (3 and 4 months) (Figure 3). After reaching the minimum QoL, survivors recovered to a 254 higher level (see the mean OoL at 6 and 12 months and later time points). However, according to recently established TCIs<sup>33</sup> for the EORTC QLQ-C30 functioning and symptom scales, 40% and 255 256 35% of patients presented scores within ranges that indicate clinically important troubles related to 257 physical and cognitive functioning respectively, 36 months post-diagnosis. Additionally, 30% 258 reported fatigue and 39% indicated experiencing pain over the respective TCIs (see Table 4). Table 5 259 displays the data for the head and neck module, showing that the highest median scores among the 260 EORTC QLQ-H&N35 scales were for dry mouth, coughing, sticky saliva, and reduced sexuality, 261 with all four symptoms sharing a median value of 33.

#### 3.2 Missing data

262

263

264

265

266

267

268

269

270

271

272

The proportion of missing values depended on the type of variable. Most clinical variables (e.g., sex, age, tumour stage and location and treatment) presented low missingness of 0-6.4%. Variables collected through interviews (e.g., marital status, education level and tobacco usage) had moderate missingness of 25.9-39.3%, while QoL variables had higher missingness, 39.9-41.8% at baseline. The majority of missing data in QoL variables was related with missing of the whole questionnaire (N=1692), usually because patients did not send them back, whereas 8.8% of subjects (N=393) presented missing values only in specific QoL subscales while others were measured (See Table 6 and figure S1 in the Supplementary Information). It is important to notice that the high proportion of unfilled questionnaires is driven by patients receiving the questionnaires by post and never returning them, while most patients that returned the questionnaire answered all questions. Finally, some data

- was missing in blocks in the dataset because studies did not collect the exact same variables. Body
- 274 mass index (BMI) information was solely available for HN5000, and BD2Decide lacked data on
- education level and income. Furthermore, the UMM3 dataset did not include information on alcohol
- consumption and smoking status.
- 277 There were several associations between the frequency of missing QoL measurements and certain
- patient features (p-value < .05, Table 6). Specifically, being a female (OR: 0.88), older age (OR:
- 279 0.99), possessing a high level of education (OR: 0.48), having a high income (OR: 0.51), never being
- a smoker (OR: 0.48), being married or living with a partner (OR: 0.74), and treatment without
- 281 radiotherapy (OR: 0.80) were found to be associated with a lower frequency of missing QoL data
- 282 (see Table 6 for the full list of odds ratios).

#### 4 Discussion

- In this study, we defined and built a cohort of HNC survivors from historical data contributed from
- studies conducted in Germany, Italy, and the UK, with clear eligibility criteria and survivorship
- definition. To the best of our knowledge this is the largest cohort of HNC survivors in the world.
- We observed large interstudy heterogeneity in global health status GHS/QoL at the survivorship
- 288 baseline, i.e., at the first QoL measurement after end of treatment. Two important factors that can
- impact GHS/QoL should be considered: the time at which the baseline GHS/QoL was measured and
- 290 the amount of missingness. Usually, QoL immediately after treatment is lower than at later
- 291 timepoints<sup>36</sup>, which can explain the lower GHS/QoL in some contributing studies compared to
- others. For example, the UMM studies measured QoL just after treatment completion (3-4 months
- after diagnosis), while the HN5000 measured QoL 12 months after diagnosis, which may be several
- months after actual end of treatment for some patients. BD2Decide measured QoL 6 months after
- diagnosis, but the proportion of missing values is 50.9%. Since the missingness is related to the
- measurement, e.g., patients with the lowest GHS/QoL might not answer the questionnaire, the bias
- measurement, e.g., parents with the lowest Griss QOD inight not unswer the questionnal
- introduced can lead to a higher QoL on average than expected.
- Overall survival 1-2 years after treatment remained high on average, but there were differences
- between the studies with UMM1 having shorter survival than BD2Decide and HN5000. This may be
- related to the patient characteristics in the studies but may also be partly explained by how end-of-
- treatment (baseline) was defined in the studies. In UMM1 the baseline was at 4 months after
- diagnosis, while the baseline was later in BD2Decide (at 6 months after diagnosis) and in HN5000
- 303 (12 months after diagnosis).
- Regarding the QoL trajectory over time, we observe a dip in GHS/QoL around treatment, followed
- 305 by an increase after treatment and a flattening out over time. This pattern has also been observed in
- previous studies<sup>37–39</sup>. Based on the EORTC QLQ-H&N35 scales, the most prominent concerns for
- 307 this cohort are related to physical symptoms such as dry mouth, sticky saliva, and coughing.
- We identified being female, older age, high education level, high income, and not smoking as factors
- 309 associated with lower probability of not completing the GHS/QoL scale. This highlights the
- 310 importance of proper missing data handling for improving the interpretability and analysis of QoL
- 311 data in this population, as complete case approaches can introduce selection bias and impact the
- 312 validity of the results. Furthermore, it is important to acknowledge the presence of data missing in
- blocks in the dataset, defined as structured missingness (SM)<sup>40</sup>. SM can be caused by several reasons,
- 314 but it arises naturally when integrating multisource data due to studies collecting different sets of
- variables to address different research questions. This is a missing pattern that is becoming more

- 316 common due to the increase in use of multisource data integration for machine learning models
- development. In the BD4QoL data SM is also present due to patients who never received the
- 318 questionnaires or never returned them by post.
- 319 The BD4QoL historical cohort has several important strengths. It is to date the largest dataset on
- 320 HNC survivors with 4448 subjects. The BD4QoL study is composed mainly by HNC survivors from
- 321 3 countries in Europe (Italy, Germany, and UK), in addition to smaller groups from many countries
- 322 in different continents (Americas, Asia and Europe) included in the UMM3 study. This provides a
- 323 dataset with rich demographics and regional variations. The data contains repeated QoL
- measurements acquired at various timepoints giving opportunity to unveil the longitudinal course of
- 325 QoL in HNC survivors. The standardized and validated EORTC QLQ-C30 and the head and neck
- modules H&N35/43 were applied in all studies integrated in the BD4QoL cohort, which provides
- rich information about multidomain QoL. This can be used to describe HNC survivors, identify their
- needs to improve patient care and long-term QoL. The data providers maintained high quality data
- standards in the original studies, which consequently make the integrated BD4QoL data of excellent
- 330 quality as well.
- Nonetheless, it is important to state weaknesses in this study that can limit the scope of potential
- future analyses. Most of the survivors in the BD4QoL historical cohort are white Europeans, with the
- 333 Global South and other ethnicities being underrepresented though this represents the population
- 334 where the studies were conducted. The number of questionnaires that were not returned by the
- patients and the patterns of missing data identified have the potential to introduce biases in future
- analyses, so missing data handling strategies should be carefully considered. In addition, structured
- missingness is present which requires specialized methods if the affected variables are kept in the
- analyses 41,42. The heterogeneity in the time of which patients are considered survivors whether after
- 339 3, 4, 6, or 12 months is also a challenging aspect in this data. All patients are survivors, but those
- 340 who have survived for longer, like 12 months, may not only have different QoL but also a greater
- 341 likelihood of surviving even longer.

## 5 Findings to date

342

351

- 343 Time is often a neglected variable in clinical studies, but it has a clear impact in PROs<sup>43</sup>. Instruments
- measuring PROs are administered at various timepoints across studies due to the different research
- 345 questions and assumed intervention effects. Quality of life measurements are sensitive to time of
- 346 collection and impose a challenge for interoperability when different datasets are to be integrated.
- However, measuring QoL "as often as possible", which is sometimes done, is also not a solution for
- this problem because study participants then lose the motivation to complete the forms properly and
- 349 completely. As a rule of thumb, about 4 times a year in the first year after diagnosis and once a year
- after that are usually acceptable by patients.

## **6** Ethics statement

- 352 Our study was conducted in full accordance with ethical principles, including the World Medical
- Association's Declaration of Helsinki (2002 version). The study protocol received ethical approval by
- 354 the Norwegian Regional Committee for Medical and Health Research Ethics (REK) South-East D
- under application number 154191. The data is stored in compliance with GDPR legislation in the
- secure server for sensitive data at the University of Oslo (TSD/USIT) and access is granted to
- 357 authorised collaborators included in the ethical approval. Each individual study that provided data

- received ethical approval from local authorities in Italy, Germany, the UK, and all further countries
- involved. The data providers submitted copies of these ethical approvals to the principal investigator.
- 360 BD2Decide study was approved by institutional research ethics board with identifier N. INT 65/16.
- 361 The HN5000 study was approved by the National Research Ethics Committee (South West Frenchay
- 362 Ethics Committee, reference number 10/H0107/57, 5 November 2010) and the Research and
- 363 Development departments of participating NHS Trusts. Informed consent was obtained from all
- patients recruited to HN5000.
- 365 UMM1 and UMM2 received ethical approval from the Leipzig University Ethics Committee. UMM3
- 366 was approved by Landesa Tztekammer Rheinland-Pfalz ethics committee under approval number
- 367 837.281.14 (9520).

379

380

## 7 Conflict of Interest

- 369 Marissa LeBlanc reports receiving a speaker fee from MSD unrelated to the content of this work.
- 370 Susanne Singer reports receiving honoraria for reviewing journal papers for the Quality-of-life-prize
- of Lilly, outside of this work. Lisa Licitra declares research funds to the institute for clinical studies
- 372 from Astrazeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm
- 373 International SA, Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD,
- 374 Novartis, Pfizer, Roche, Buran, Alentis; occasional fees for participation as a speaker at
- 375 conferences/congresses or as a scientific consultant for advisory boards from Astrazeneca, Bayer,
- 376 MSD, Merck-Serono, AccMed, Neutron Therapeutics, Inc.
- 377 The remaining authors declare that the research was conducted in the absence of any commercial or
- financial relationships that could be construed as a potential conflict of interest.

#### **8** Author Contributions

- 381 MMS, KT, SS, KH, ST, AN, CV, LL-P, MFC-U, GF, LL, ML contributed to the conceptualization of
- the study. SS, KH, ST, AN, MFC-U, AF, LL, ML were responsible for funding acquisition. KT, SS,
- 383 KH, ST, MP, AN, SC, LL conducted data sharing. MMS, EIFF, AF, ML participated in the
- investigation process. MMS, EIFF developed and/or worked with the necessary software. MMS,
- 385 EIFF, KT, CV, ML crafted the methodology framework of the study. LL-P, AF, LL provided the
- resources needed for the research. All authors contributed to writing the manuscript.

## **387 9 Funding**

- 388 The BD4QoL project, in the frame of which this work is being conducted, has received funding from
- 389 the European Union's Horizon 2020 research and innovation program under grant agreement No
- 390 875192. MM-S received funding from the European Union's Horizon 2020 Research and Innovation
- 391 program under the Marie Skłodowska-Curie Actions Grant, agreement No. 80113 (Scientia
- fellowship). This Publication presents data from the Head and Neck 5000 study. The study was a
- 393 component of independent research funded by the National Institute for Health and Care Research
- 394 (NIHR) under its programme Grands for applied Research scheme (RP-PG-070-10034). The views
- expressed in this publication are those of the author(s) and are not necessarily those of the NHS, the
- 396 NIHR or the department of health and Social Care. Core funding was also provided through awards

- from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and
- 398 the NIHR Senior Investigator award to Professor Andy Ness. The UMM1 study was funded by the
- 399 German Federal Ministry of Education and Science (Grant Number: 7DZAIQTX), the UMM1 and
- 400 UMM2 study by the German Cancer Aid (Grant Numbers #106654, #107440, #108758, #109604),
- 401 the UMM3 study by the European Organisation for Research and Treatment of Cancer (Grant
- 402 Number: 001/2014).

417

## 10 Acknowledgments

- 404 This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the
- 405 University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-
- 406 Department (USIT). The statistical analysis and data harmonisation were performed on resources
- 407 provided by Sigma2 the National Infrastructure for High Performance Computing and Data Storage
- in Norway. The Authors thank the researchers and clinicians who designed the BD2Decide, HN5000,
- and Mainz studies, the research, laboratory and clinical staff who supported the conduct of the
- studies; and the people with head and neck cancer who took part.

## 411 **11 Data Availability Statement**

- The BD4QoL historical cohort dataset is hosted by the Services for Sensitive Data (TSD) at the
- 413 University of Oslo. Access to the data may be granted by the data owners upon application.
- The data that support the findings of this study are available from head and neck 5000. Further
- 415 information may be found on the Head and Neck 5000 website: https://www.headand
- 416 neck5000.org.uk/information-for-researchers.

## **Tables**

Table 1 - Historical datasets included in BD4QoL. Study ID is the ID used in this manuscript; study short name is the original short study name. Shown are the number of cases before eligibility filtering (N), the number of eligible cases according to the eligibility criteria in this study (Eligible). Eligible number of cases could not be assessed for BD2Decide because a selection was made prior to data transfer.

Study ID	Study short name	References	Region	N	Eligible
HN5000	HN5000	25,26	UK	5404	3572
UMM1	TLE	27	DE	473	180
UMM2	PLE	28	DE	468	426
UMM3	HN43 Phase IV	29	DE	812	158
INT	BD2Decide	30	IT	119	112*
Total	BD4QoL		EU	7276	4448

<sup>\*</sup>The data was filtered for QoL availability before data transfer (INT)

Table 2 – Planned data collection per study. All studies collected data at diagnosis/before treatment (0 months), but end of treatment varies across study. UMM studies recorded end of treatment, either with start of patient rehabilitation or hospital discharge at approximately 4 months. In BD2Decide and HN5000 study all patients are assumed to have concluded treatment before 6 and 12 months respectively.

study/time (months)	0	3	4	6	12	18	24	36
BD2Decide	X			ЕоТ		X	X	
UMM1	X		ЕоТ	X	X		X	X
UMM2	X		ЕоТ	X	X			
UMM3	X	ЕоТ		x				
HN5000	X		X		ЕоТ			X

EoT - End of treatment

## Table 3 – Baseline cohort characteristics for the BD4QoL historical cohort stratified by study.

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Sex, n (%)						
1 - Male	85 (76)	163 (91)	390 (92)	118 (75)	2,694 (75)	3,450 (78)
2 - Female	27 (24)	17 (9.4)	36 (8.5)	40 (25)	878 (25)	998 (22)
Age at diagnosis	59 (53, 67)	55 (50, 64)	63 (54, 71)	66 (57, 73)	61 (54, 68)	61 (54, 68)
Missing	0	26	108	0	0	134
Education level, n (%)						
1 - Low	0 (NA)	75 (52)	147 (45)	54 (37)	1,197 (47)	1,473 (47)
2 - Medium	0 (NA)	50 (35)	133 (41)	25 (17)	886 (35)	1,094 (35)
3 - High	0 (NA)	19 (13)	47 (14)	66 (46)	450 (18)	582 (18)
Missing	112	36	99	13	1,039	1,299
Household income (€/month), n (%)						
1 - Less than 500	0 (NA)	19 (17)	8 (2.9)	0 (NA)	367 (16)	394 (15)
2 - 500 - 1500	0 (NA)	50 (43)	97 (36)	0 (NA)	696 (30)	843 (31)
3 - 1501 - 2500	0 (NA)	36 (31)	113 (42)	0 (NA)	480 (21)	629 (23)
4 - 2501 - 3500	0 (NA)	7 (6.1)	42 (15)	0 (NA)	188 (8.1)	237 (8.8)
5 - more than 3500	0 (NA)	3 (2.6)	12 (4.4)	0 (NA)	581 (25)	596 (22)
Missing	112	65	154	158	1,260	1,749
Body mass index	NA	NA	NA	NA	26 (23, 29)	26 (23, 29)
Missing	112	180	426	158	1,064	1,940
Marital status, n (%)						
1 - Single	0 (NA)	23 (16)	32 (9.8)	51 (32)	331 (12)	437 (13)
2 - Married/Living with a partner	0 (NA)	90 (62)	214 (65)	107 (68)	1,830 (69)	2,241 (68)
3 - Divorced/Separated	0 (NA)	23 (16)	58 (18)	0 (0)	327 (12)	408 (12)
4 - Widowed	0 (NA)	9 (6.2)	23 (7.0)	0 (0)	177 (6.6)	209 (6.3)
Missing	112	35	99	0	907	1,153
Smoker status at diagnosis, n (%)						
1 - Current	38 (34)	34 (24)	74 (34)	0 (NA)	500 (20)	646 (21)
2 - Former	39 (35)	100 (69)	121 (55)	0 (NA)	1,487 (58)	1,747 (57)
3 - Never	35 (31)	10 (6.9)	24 (11)	0 (NA)	577 (23)	646 (21)
Missing	0	36	207	158	1,008	1,409
Units of alcohol per month	193 (129, 451)	47 (0, 159)	53 (5, 160)	NA	88 (36, 172)	84 (28, 172)
Missing	80	40	209	158	1,558	2,045

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Tumour location, n (%)	<u>-</u>	•	•	<u>-</u>	•	
1 - Oral cavity	25 (22)	0 (0)	0 (0)	83 (53)	971 (27)	1,079 (24)
2 - Oropharynx	66 (59)	0 (0)	2 (0.5)	0 (0)	1,509 (42)	1,577 (35)
3 - Nasopharynx	0 (0)	0 (0)	0 (0)	0 (0)	69 (1.9)	69 (1.6)
4 - Hypopharynx	6 (5.4)	25 (14)	16 (3.8)	21 (13)	135 (3.8)	203 (4.6)
5 - Larynx	15 (13)	140 (78)	390 (92)	49 (31)	844 (24)	1,438 (32)
6 - Nasal cavity and paranasal sinuses	0 (0)	0 (0)	0 (0)	5 (3.2)	44 (1.2)	49 (1.1)
7 - Overlapping several areas	0 (0)	15 (8.3)	18 (4.2)	0 (0)	0 (0)	33 (0.7)
UICC 7th Ed., n (%)						
1 - I	0 (0)	5 (3.0)	211 (53)	34 (26)	851 (24)	1,101 (25)
2 - II	0 (0)	20 (12)	97 (24)	23 (18)	661 (19)	801 (18)
3 - III	21 (19)	45 (27)	32 (8.1)	20 (15)	497 (14)	615 (14)
4 - IV	91 (81)	97 (58)	57 (14)	53 (41)	1,554 (44)	1,852 (42)
Missing	0	13	29	28	9	79
Surgery, n (%)						
1 - Yes	39 (35)	168 (94)	171 (40)	82 (55)	1,430 (40)	1,890 (43)
2 - No	73 (65)	10 (5.6)	254 (60)	66 (45)	2,142 (60)	2,545 (57)
Missing	0	2	1	10	0	13
Radiotherapy, n (%)						
1 - Yes	112 (100)	115 (80)	76 (32)	99 (63)	2,742 (77)	3,144 (75)
2 - No	0 (0)	29 (20)	163 (68)	59 (37)	822 (23)	1,073 (25)
Missing	0	36	187	0	8	231
Chemotherapy, n (%)						
1 - Yes	89 (79)	15 (20)	29 (11)	43 (27)	1,520 (43)	1,696 (41)
2 - No	23 (21)	61 (80)	228 (89)	114 (73)	2,042 (57)	2,468 (59)
Missing	0	104	169	1	10	284
Country, n (%)						
Brazil	0 (0)	0 (0)	0 (0)	10 (6.3)	0 (0)	10 (0.2)
Egypt	0 (0)	0 (0)	0 (0)	4 (2.5)	0 (0)	4 (<0.1)
Germany	0 (0)	180 (100)	426 (100)	14 (8.9)	0 (0)	620 (14)
Israel	0 (0)	0 (0)	0 (0)	6 (3.8)	0 (0)	6 (0.1)
Italy	112 (100)	0 (0)	0 (0)	12 (7.6)	0 (0)	124 (2.8)
Japan	0 (0)	0 (0)	0 (0)	1 (0.6)	0 (0)	1 (<0.1)

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Norway	0 (0)	0 (0)	0 (0)	22 (14)	0 (0)	22 (0.5)
Poland	0 (0)	0 (0)	0 (0)	10 (6.3)	0 (0)	10 (0.2)
Portugal	0 (0)	0 (0)	0 (0)	9 (5.7)	0 (0)	9 (0.2)
Spain	0 (0)	0 (0)	0 (0)	7 (4.4)	0 (0)	7 (0.2)
Sweden	0 (0)	0 (0)	0 (0)	35 (22)	0 (0)	35 (0.8)
UK	0 (0)	0 (0)	0 (0)	21 (13)	3,572 (100)	3,593 (81)
USA	0 (0)	0 (0)	0 (0)	7 (4.4)	0 (0)	7 (0.2)

<sup>&</sup>lt;sup>1</sup>n (%); Median (IQR)

436

Table 4 – EORTC QLQ-C30 questionnaire scales stratified by study.

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Physical Functioning	93 (86, 100)	80 (53, 86)	80 (66, 93)	80 (60, 93)	86 (66, 100)	86 (66, 100)
Missing	57	70	194	25	1,485	1,831
Role Functioning	100 (92, 100)	66 (33, 100)	66 (50, 100)	66 (33, 100)	83 (66, 100)	83 (66, 100)
Missing	57	71	195	25	1,471	1,819
Cognitive Functioning	100 (83, 100)	100 (66, 100)	100 (66, 100)	100 (83, 100)	83 (66, 100)	83 (66, 100)
Missing	57	70	194	29	1,448	1,798
Emotional Functioning	91 (75, 100)	75 (50, 91)	75 (50, 91)	75 (58, 91)	83 (66, 100)	83 (66, 100)
Missing	57	70	194	29	1,464	1,814
Social Functioning	100 (100, 100)	66 (50, 100)	83 (50, 100)	83 (50, 100)	83 (66, 100)	83 (66, 100)
Missing	57	70	194	28	1,457	1,806
Fatigue	11 (0, 33)	33 (11, 55)	33 (11, 55)	33 (22, 55)	33 (11, 44)	33 (11, 44)
Missing	57	70	195	25	1,454	1,801
Pain	0 (0, 16)	33 (0, 50)	16 (0, 37)	33 (0, 50)	16 (0, 33)	16 (0, 33)
Missing	57	70	194	26	1,461	1,808
Nausea/Vomiting	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 16)	0 (0, 0)	0 (0, 0)
Missing	57	70	195	25	1,449	1,796
Diarrhoea	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Missing	57	71	194	29	1,443	1,794
Constipation	NA (NA, NA)	0 (0, 0)	0 (0, 0)	0 (0, 33)	0 (0, 33)	0 (0, 33)
Missing	112	70	194	30	1,442	1,848

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Appetite Loss	NA (NA, NA)	0 (0, 33)	0 (0, 33)	33 (0, 66)	0 (0, 33)	0 (0, 33)
Missing	112	70	196	25	1,456	1,859
Insomnia	NA (NA, NA)	0 (0, 66)	33 (0, 66)	33 (0, 66)	33 (0, 33)	33 (0, 33)
Missing	112	70	195	26	1,442	1,845
Dyspnoea	0 (0, 33)	33 (0, 66)	33 (0, 33)	0 (0, 33)	0 (0, 33)	0 (0, 33)
Missing	57	70	195	25	1,447	1,794
Financial Impact	0 (0, 0)	33 (0, 66)	33 (0, 66)	0 (0, 33)	0 (0, 33)	0 (0, 33)
Missing	57	70	196	29	1,447	1,799
GHS/QoL	83 (75, 87)	50 (41, 75)	50 (33, 66)	58 (50, 75)	75 (58, 83)	66 (50, 83)
Missing	57	65	179	29	1,444	1,774
GHS/QoL	83 (75, 87)	50 (41, 75)	50 (33, 66)	58 (50, 75)	75 (58, 83)	66 (50, 83)
Missing	57	65	179	29	1,444	1,774

<sup>&</sup>lt;sup>1</sup>Median (IQR)

## Table 5 – EORTC QLQ-H&N35 module scales stratified by study.

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Pain	8 (0, 25)	16 (0, 50)	16 (0, 41)	16 (8, 35)	8 (0, 25)	16 (0, 33)
Missing	60	61	181	26	1,502	1,830
Swallowing Problems	8 (0, 16)	16 (0, 41)	8 (0, 46)	0 (0, 33)	8 (0, 25)	8 (0, 25)
Missing	60	63	183	30	1,484	1,820
Senses Problems	16 (0, 33)	66 (50, 100)	0 (0, 16)	33 (0, 54)	16 (0, 50)	16 (0, 50)
Missing	60	61	178	26	1,453	1,778
Speech Problems	11 (0, 22)	66 (36, 77)	55 (33, 88)	26 (13, 46)	11 (0, 33)	22 (0, 44)
Missing	60	66	179	31	1,479	1,815
Trouble with social eating	8 (0, 16)	25 (6, 50)	0 (0, 25)	25 (4, 50)	16 (0, 41)	16 (0, 41)
Missing	60	64	183	31	1,491	1,829
Trouble with social contact	0 (0, 6)	13 (0, 40)	6 (0, 20)	0 (0, 33)	0 (0, 13)	0 (0, 20)
Missing	60	60	179	33	1,486	1,818
Less Sexuality	0 (0, 33)	33 (0, 66)	33 (0, 66)	16 (0, 66)	33 (0, 66)	33 (0, 66)
Missing	60	73	196	39	1,696	2,064
Teeth Problems	0 (0, 33)	0 (0, 33)	0 (0, 0)	22 (0, 44)	0 (0, 33)	0 (0, 33)
Missing	60	63	178	27	1,486	1,814
Opening Mouth	0 (0, 33)	0 (0, 66)	0 (0, 0)	0 (0, 33)	0 (0, 33)	0 (0, 33)
Missing	60	61	179	27	1,447	1,774
Dry Mouth	33 (33, 66)	33 (0, 66)	100 (0, 100)	33 (16, 66)	33 (33, 92)	33 (33, 100)
Missing	60	62	179	26	1,446	1,773
Sticky Saliva	33 (33, 66)	33 (0, 66)	100 (0, 200)	2 (1, 3)	33 (0, 66)	33 (0, 66)
Missing	60	62	180	27	1,458	1,787
Coughing	0 (0, 33)	66 (33, 74)	100 (100, 200)	0 (0, 33)	33 (0, 33)	33 (0, 66)
Missing	60	60	180	26	1,449	1,775
Felt III	0 (0, 0)	33 (0, 66)	100 (0, 200)	NA (NA, NA)	0 (0, 33)	0 (0, 33)
Missing	60	61	180	158	1,453	1,912
Pain Killers	33 (25, 33)	0 (0, 100)	0 (0, 100)	NA (NA, NA)	0 (0, 100)	0 (0, 100)
Missing	60	58	178	158	1,449	1,903
Nutritional Supplements	33 (33, 33)	0 (0, 0)	0 (0, 0)	NA (NA, NA)	0 (0, 100)	0 (0, 100)
Missing	60	59	180	158	1,454	1,911
Feeding Tube	33 (33, 33)	0 (0, 100)	0 (0, 0)	NA (NA, NA)	0 (0, 0)	0 (0, 0)
Missing	60	58	180	158	1,458	1,914

Characteristic	<b>INT</b> N = 112 <sup>1</sup>	<b>UMM1</b> N = 180 <sup>1</sup>	<b>UMM2</b> N = 426 <sup>1</sup>	<b>UMM3</b> N = 158 <sup>1</sup>	<b>UOB</b> N = 3572 <sup>1</sup>	<b>Overall</b> N = 4448 <sup>1</sup>
Weight Loss	33 (33, 33)	0 (0, 100)	0 (0, 100)	0 (0, 33)	0 (0, 0)	0 (0, 0)
Missing	60	60	180	29	1,473	1,802
Weight Gain	33 (33, 33)	0 (0, 100)	0 (0, 0)	NA (NA, NA)	0 (0, 100)	0 (0, 100)
Missing	60	59	181	158	1,508	1,966

<sup>&</sup>lt;sup>1</sup>Median (IQR)


442

Table 6 - Odds ratios (OR) and p-values from univariate logistic regression models with response "Missing GHS/QoL" given the respective covariate in the table.


	OR	p-value
Sex		
Male	_	_
Female	0.88	<.001
Age	0.99	<.001
Education level		
Low	_	_
Medium	0.81	0.02
High	0.51	<.001
Income		
Less than 500	_	_
500 - 1500	0.74	0.02
1501 - 2500	0.64	0.001
2501 - 3500	0.65	0.02
More than 3500	0.50	<.001
Body mass index	0.99	0.05
Marital status		
Single	_	_
Married/Living with a partner	0.74	0.01
Divorced/Separated	1.07	0.62
Widowed	0.82	0.28
Smoker status at the baseline		
Current	_	_
Former	0.55	<.001
Never	0.48	<.001
Units of alcohol per month	1.00	0.002
Tumour stage (TNM 7 <sup>th</sup> Ed)		
I	_	_
II	1.20	0.04
Ш	1.00	0.89
IV	1.11	0.15
Tumour region		
Oral cavity	_	_
Oropharynx	0.94	0.47

Nasopharynx	0.87	0.58
Hypopharynx	1.10	0.28
Larynx	1.09	0.28
Overlapping several areas	1.27	0.50
Nasal cavity and paranasal sinuses	1.05	0.86
Radiotherapy		
Yes	_	
No	0.80	0.002
Chemotherapy		
Yes	_	_
No	0.94	0.31
Surgery		
Yes	_	_
No	0.99	0.83

# **Figures**



**Figure 1** – Cohort flowchart for the entire BD4QoL cohort. See Supplementary Information for flowcharts for each study.



**Figure 2** – Kaplan-Meier curves with 95% confidence interval for BD2Decide, UMM1 and HN5000 studies showing 2 years overall survival after treatment. Other studies did not have the necessary time to event data for inclusion in the curve.

# Overall quality of life over Time Mean and Boostrapped 95% Confidence Intervals 80 EORTC QLQ-C30 Pain Study BD2Decide H&N5000 UMM1 UMM2 UMM3 50 3 12 18 24 36 Time from study enrollment (months)

Figure 3 – Global QoL trajectories conditional on survival and measured QoL per study. The baseline for UMM1 and UMM2 is at 4 months, UMM3 is at 3 months, BD2Decideis at 6 months, and HN5000 at 12 months. Measurements at time 0 are before treatment and all measurements before the respective baselines are for patients that survived treatment and completed the questionnaires. Patients with missing global QoL were not considered in this figure.

473

474

475476

477

478

479

480

## 12 References

- 1. Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. *The Lancet*.
- 484 2021;398(10318):2289-2299. doi:10.1016/S0140-6736(21)01550-6
- 2. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and
- 486 years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a
- 487 systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*.
- 488 2017;390(10100):1211-1259. doi:10.1016/S0140-6736(17)32154-2
- 3. Mehanna H, Paleri V, West CML, Nutting C. Head and neck cancer--Part 1: Epidemiology,
- 490 presentation, and prevention. *BMJ*. 2010;341(sep20 1):c4684-c4684. doi:10.1136/bmj.c4684
- 491 4. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021;149(4):778-789. doi:10.1002/ijc.33588
- 5. Pulte D, Brenner H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early
- 494 21st Century: A Period Analysis. *The Oncologist*. 2010;15(9):994-1001.
- 495 doi:10.1634/theoncologist.2009-0289
- 496 6. Høxbroe Michaelsen S, Grønhøj C, Høxbroe Michaelsen J, Friborg J, von Buchwald C. Quality of
- life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366
- 498 patients. European Journal of Cancer. 2017;78:91-102. doi:10.1016/j.ejca.2017.03.006
- 7. Ramqvist T, Dalianis T. Oropharyngeal Cancer Epidemic and Human Papillomavirus. *Emerg*
- 500 Infect Dis. 2010;16(11):1671-1677. doi:10.3201/eid1611.100452
- 8. Carlander ALF, Grønhøj Larsen C, Jensen DH, et al. Continuing rise in oropharyngeal cancer in a
- high HPV prevalence area: A Danish population-based study from 2011 to 2014. European
- Journal of Cancer. 2017;70:75-82. doi:10.1016/j.ejca.2016.10.015
- 9. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival of Patients with
- 505 Oropharyngeal Cancer. *N Engl J Med*. 2010;363(1):24-35. doi:10.1056/NEJMoa0912217
- 506 10. Patel MA, Blackford AL, Rettig EM, Richmon JD, Eisele DW, Fakhry C. Rising population of
- survivors of oral squamous cell cancer in the United States: Rising Oral Cancer Survivors in the
- 508 US. Cancer. 2016;122(9):1380-1387. doi:10.1002/cncr.29921
- 509 11. Goyal N, Day A, Epstein J, et al. Head and neck cancer survivorship consensus statement from
- the American Head and Neck Society. *Laryngoscope Investig Oto*. 2022;7(1):70-92.
- 511 doi:10.1002/lio2.702
- 512 12. Forastiere A, Koch W, Trotti A, Sidransky D. Head and Neck Cancer. N Engl J Med.
- 513 2001;345(26):1890-1900. doi:10.1056/NEJMra001375
- 13. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer.
- 515 Annals of Oncology. 2010;21:vii252-vii261. doi:10.1093/annonc/mdq453

- 516 14. Strojan P, Hutcheson KA, Eisbruch A, et al. Treatment of late sequelae after radiotherapy for
- head and neck cancer. Cancer Treatment Reviews. 2017;59:79-92.
- 518 doi:10.1016/j.ctrv.2017.07.003
- 519 15. Alterio D, Jereczek-Fossa BA, Franchi B, et al. Thyroid disorders in patients treated with
- radiotherapy for head-and-neck cancer: A retrospective analysis of seventy-three patients.
- 521 International Journal of Radiation Oncology\*Biology\*Physics. 2007;67(1):144-150.
- 522 doi:10.1016/j.ijrobp.2006.08.051
- 523 16. Taylor K, Krüger M, Singer S. Long-term toxicity among head and neck cancer patients—A
- 524 systematic review. *Onkologe*. 2021;27(S2):145-149. doi:10.1007/s00761-021-00914-x
- 525 17. Quinten C, Martinelli F, Coens C, et al. A global analysis of multitrial data investigating quality
- of life and symptoms as prognostic factors for survival in different tumor sites. *Cancer*.
- 527 2014;120(2):302-311. doi:10.1002/cncr.28382
- 528 18. van Nieuwenhuizen AJ, Buffart LM, Brug J, René Leemans C, Verdonck-de Leeuw IM. The
- association between health related quality of life and survival in patients with head and neck
- cancer: A systematic review. *Oral Oncology*. 2015;51(1):1-11.
- 531 doi:10.1016/j.oraloncology.2014.09.002
- 19. So W, Chan R, Chan D, et al. Quality-of-life among head and neck cancer survivors at one year
- after treatment–a systematic review. *European journal of cancer*. 2012;48(15):2391-2408.
- 534 20. Taylor KJ, Amdal CD, Bjordal K, et al. Serious Long-Term Effects of Head and Neck Cancer
- from the Survivors' Point of View. *Healthcare*. 2023;11(6):906.
- 536 doi:10.3390/healthcare11060906
- 21. Alonso I, Lopez-Perez L, Guirado JCM, Cabrera-Umpierrez MF, Arredondo MT, Fico G. Data
- analytics for predicting quality of life changes in head and neck cancer survivors: a scoping
- review. In: 2021 43rd Annual International Conference of the IEEE Engineering in Medicine &
- 540 *Biology Society (EMBC)*. IEEE; 2021:2262-2265.
- 541 22. Taylor K, Singer S. Long-term quality of life in head and neck cancer patients: A systematic
- review. Onkologe. 2019;25(S2):125-131. doi:10.1007/s00761-019-0527-z
- 543 23. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and
- Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical
- Trials in Oncology. *JNCI Journal of the National Cancer Institute*. 1993;85(5):365-376.
- 546 doi:10.1093/jnci/85.5.365
- 547 24. Fayers P, Aaronson NK, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. European
- Organisation for Research and Treatment of Cancer; 1995.
- 549 25. The Head and Neck 5000 Study Team, Ness AR, Waylen A, et al. Establishing a large
- prospective clinical cohort in people with head and neck cancer as a biomedical resource: head
- and neck 5000. *BMC Cancer*. 2014;14(1):973. doi:10.1186/1471-2407-14-973

- 552 26. Ness AR, Waylen A, Hurley K, et al. Recruitment, response rates and characteristics of 5511
- people enrolled in a prospective clinical cohort study: head and neck 5000. *Clinical*
- 554 *Otolaryngology*. 2016;41(6):804-809. doi:https://doi.org/10.1111/coa.12548
- 555 27. Singer S, Danker H, Guntinas–Lichius O, et al. Quality of life before and after total
- laryngectomy: Results of a multicenter prospective cohort study. *Head & Neck.* 2014;36(3):359-
- 557 368. doi:10.1002/hed.23305
- 28. Clasen D, Keszte J, Dietz A, et al. Quality of life during the first year after partial laryngectomy:
- 559 Longitudinal study. *Head & Neck.* 2018;40(6):1185-1195. doi:10.1002/hed.25095
- 560 29. Singer S, Amdal CD, Hammerlid E, et al. International validation of the revised European
- Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC
- 562 QLQ HN43: Phase IV. Head & Neck. 2019;41(6):1725-1737. doi:10.1002/hed.25609
- 30. Cavalieri S, De Cecco L, Brakenhoff RH, et al. Development of a multiomics database for
- personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project.
- 565 *Head & neck.* 2021;43(2):601-612.
- 31. Compton SEC, Cancer AJC on, others. the 7th edition of the AJCC cancer staging manual and
- the future of TNM Ann. *Surg Oncol*. 17:1471-1474.
- 32. Almeida A, Bilbao-Jayo A, Hernandez L, et al. An Ontology for Quality of Life Modeling in
- Head and Neck Cancer. In: 2022 7th International Conference on Smart and Sustainable
- 570 *Technologies (SpliTech)*. IEEE; 2022:1-5. doi:10.23919/SpliTech55088.2022.9854379
- 33. Giesinger JM, Loth FLC, Aaronson NK, et al. Thresholds for clinical importance were
- established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.
- 573 *Journal of Clinical Epidemiology*. 2020;118:1-8. doi:10.1016/j.jclinepi.2019.10.003
- 34. Lopez-Perez L, Hernández L, Ottaviano M, et al. BD2Decide: Big Data and Models for
- Personalized Head and Neck Cancer Decision Support. In: 2019 IEEE 32nd International
- 576 Symposium on Computer-Based Medical Systems (CBMS).; 2019:67-68.
- 577 doi:10.1109/CBMS.2019.00024
- 578 35. Hernández L, Estévez-Priego E, López-Pérez L, et al. HeNeCOn: An ontology for integrative
- research in Head and Neck cancer. *International Journal of Medical Informatics*.
- 580 2024;181:105284. doi:10.1016/j.ijmedinf.2023.105284
- 36. Sandstrom, RN, MSN, APRN-BC, AOCN SK, R. Mazanec, PhD, RN, AOCN S, Gittleman, MS
- 582 H, S. Barnholtz-Sloan, PhD J, Tamburro, LISW-S N, J. Daly, PhD, RN, FAAN B. A Descriptive,
- Longitudinal Study of Quality of Life and Perceived Health Needs in Patients With Head and
- Neck Cancer. *JADPRO*. 2016;7(6). doi:10.6004/jadpro.2016.7.6.6
- 585 37. de Vries J, Bras L, Sidorenkov G, et al. Frailty is associated with decline in health-related quality
- of life of patients treated for head and neck cancer. *Oral Oncology*. 2020;111:105020.
- 587 doi:10.1016/j.oraloncology.2020.105020
- 38. Abel E, Silander E, Nordström F, et al. Fatigue in Patients With Head and Neck Cancer Treated
- With Radiation Therapy: A Prospective Study of Patient-Reported Outcomes and Their

Association With Radiation Dose to the Cerebellum. *Advances in Radiation Oncology*.

- 591 2022;7(5):100960. doi:10.1016/j.adro.2022.100960
- 39. Braam PM, Roesink JM, Raaijmakers CP, Busschers WB, Terhaard CH. Quality of life and
- salivary output in patients with head-and-neck cancer five years after radiotherapy. *Radiat Oncol*.
- 594 2007;2(1):3. doi:10.1186/1748-717X-2-3
- 595 40. Mitra R, McGough SF, Chakraborti T, et al. Learning from data with structured missingness. *Nat Mach Intell*. 2023;5(1):13-23. doi:10.1038/s42256-022-00596-z
- 41. Kamphuis R, Jolani S, Lugtig P. The Blocked Imputation Approach for Missing Data. Published online 2018. doi:10.13140/RG.2.2.12467.32803
- 599 42. Tierney NJ, Harden FA, Harden MJ, Mengersen KL. Using decision trees to understand structure in missing data. *BMJ Open*. 2015;5(6):e007450. doi:10.1136/bmjopen-2014-007450
- 43. J. Pater, D. Osoba, B. Zee, et al. Effects of Altering the Time of Administration and the Time
- Frame of Quality of life Assessments in Clinical Trials: An Example Using the EORTC QLQ-
- 603 C30 in a Large Anti-Emetic Trial. *Quality of Life Research*. 1998;(7):273-278.
- doi:10.1023/A:1024954518241